The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer

Laryngoscope

Volumn 126, Issue 4, 2016, Pages 894-900

  Gooi, Zhen ^a   Chan, Jason Y K ^b   Fakhry, Carole ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

epidemiology; head and neck cancer; human papillomavirus; Oropharynx; squamous cell carcinoma

Indexed keywords

WART VIRUS VACCINE;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; DEMOGRAPHY; DISEASE COURSE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MEDLINE; MOUTH INFECTION; NONHUMAN; NORTH AMERICA; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VACCINATION; WESTERN EUROPE; HEAD AND NECK NEOPLASMS; INCIDENCE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; VIROLOGY;

DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS;

EID: 84959421326     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25767     Document Type: Review

References (73)

1. Muñoz N, Bosch FX, de Sanjosé S, et al., Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
2. Kreimer AR, Clifford GM, Boyle P, Franceschi S,. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475.
3. Pyeon D, Newton MA, Lambert PF, et al., Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-4619.
4. Dahlgren L, Mellin H, Wangsa D, et al., Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003; 107: 244-249.
5. Gillison ML, Koch WM, Capone RB, et al., Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
6. D'Souza G, Kreimer AR, Viscidi R, et al., Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
7. Miller DL, Puricelli MD, Stack MS,. Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma. Biochem J 2012; 443: 339-353.
8. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E,. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000; 89: 300-304.
9. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP,. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
10. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619.
11. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al., Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-4559.
12. Forte T, Niu J, Lockwood GA, Bryant HE,. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control 2012; 23: 1343-1348.
13. Shin A, Jung Y, Jung K, Kim K, Ryu J, Won Y,. Trends of human papillomavirus-related head and neck cancers in Korea: national cancer registry data. Laryngoscope 2013; 123: E30-E37.
14. Blomberg M, Nielsen A, Munk C, Kjaer SK,. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011; 129: 733-741.
15. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M,. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 2010; 116: 2635-2644.
16. Walter L, Vidaurre T, Gilman RH, et al., Trends in head and neck cancers in Peru between 1987 and 2008: experience from a large public cancer hospital in Lima. Head Neck 2014; 36: 729-734.
17. Näsman A, Attner P, Hammarstedt L, et al., Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366.
18. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
19. Mehanna H, Beech T, Nicholson T, et al., Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747-755.
20. Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR,. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-391.
21. Pickard RKL, Xiao W, Broutian TR, He X, Gillison ML,. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis 2012; 39: 559-566.
22. Kreimer AR, Villa A, Nyitray AG, et al., The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers 2011; 20: 172-182.
23. Gillison ML, Broutian T, Pickard RKL, et al., Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703.
24. Kreimer AR, Pierce Campbell CM, Lin HY, et al., Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382: 877-887.
25. D'Souza G, Gross ND, Pai SI, et al., Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 2014; 32: 2408-2415.
26. D'Souza G, Fakhry C, Sugar EA, et al., Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007; 121: 143-150.
27. D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C,. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 2014; 9: e86023.
28. Gillison ML, D'Souza G, Westra W, et al., Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
29. Benard VB, Johnson CJ, Thompson TD, et al., Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 2008; 113: 2910-2918.
30. Fakhry C, Marks MA, Gilman RH, et al., Comparison of the immune microenvironment of the oral cavity and cervix in healthy women. Cytokine 2013; 64: 597-604.
31. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
32. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
33. Guo T, Qualliotine JR, Ha PK, et al., Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 2015; 121: 1977-1984.
34. Fakhry C, Zhang Q, Nguyen-Tan PF, et al., Reply to B. O'Sullivan et al. J Clin Oncol 2015; 33: 1708-1709.
35. Ang KK, Zhang Q, Rosenthal DI, et al., Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940-2950.
36. Fakhry C, Zhang Q, Nguyen-Tan PF, et al., Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014; 32: 3365-3373.
37. Argiris A, Li S, Ghebremichael M, et al., Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 2014; 25: 1410-1416.
38. Muñoz N, Kjaer SK, Sigurdsson K, et al., Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339.
39. Giuliano AR, Palefsky JM, Goldstone S, et al., Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401-411.
40. Herrero R, Quint W, Hildesheim A, et al., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013; 8: e68329.
41. Curtis CR, Dorell C, Yankey D, et al., National human papillomavirus vaccination coverage among adolescents aged 13-17 years-National Immunization Survey-teen, United States, 2011. MMWR Surveill Summ 2014; 63 (suppl 2): 61-70.
42. Markowitz LE, Hariri S, Lin C, et al., Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-393.
43. Merckx M, Broeck DV, Benoy I, Depuydt C, Weyers S, Arbyn M,. Early effects of human papillomavirus vaccination in Belgium. Eur J Cancer Prev 2015; 24: 340-342.
44. Deleré Y, Remschmidt C, Leuschner J, et al., Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014; 14: 87.
45. Tabrizi SN, Brotherton JML, Kaldor JM, et al., Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14: 958-966.
46. Mork J, Lie AK, Glattre E, et al., Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
47. Kreimer AR, Johansson M, Waterboer T, et al., Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013; 31: 2708-2715.
48. Fakhry C, Rosenthal BT, Clark DP, Gillison ML,. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011; 4: 1378-1384.
49. Fakhry C, Andersen KK, Christensen J, Agrawal N, Eisele DW,. The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015; 8: 583-589.
50. Kuhs KAL, Anantharaman D, Waterboer T, et al., Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2015; 24: 683-689.
51. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ,. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000; 11: 489-495.
52. Ryerson AB, Peters ES, Coughlin SS, et al., Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113 (10 suppl): 2901-2909.
53. McGorray SP, Guo Y, Logan H,. Trends in incidence of oral and pharyngeal carcinoma in Florida: 1981-2008. J Public Health Dent 2012; 72: 68-74.
54. Hospital Authority: Hong Kong Cancer Registry website. Available at: http://www3.ha.org.hk/cancereg/statistics.html. Accessed August 2015.
55. Hammarstedt L, Lindquist D, Dahlstrand H, et al., Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
56. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D,. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 1999; 109: 1544-1551.
57. Ritchie JM, Smith EM, Summersgill KF, et al., Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-344.
58. Schwartz SM, Daling JR, Doody DR, et al., Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636.
59. Strome SE, Savva A, Brissett AE, et al., Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002; 8: 1093-1100.
60. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL,. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 1997; 123: 513-516.
61. Klussmann JP, Weissenborn SJ, Wieland U, et al., Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 2875-2884.
62. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
63. Romanitan M, Nasman A, Ramqvist T, et al., Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 2008; 28: 2077-2080.
64. Tachezy R, Klozar J, Salakova M, et al., HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis 2005; 11: 181-185.
65. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT,. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8: 3187-3192.
66. Kawakami H, Okamoto I, Terao K, et al., Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. Cancer Med 2013; 2: 933-941.
67. Deng Z, Hasegawa M, Matayoshi S, et al., Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol 2011; 268: 1625-1631.
68. Mineta H, Ogino T, Amano HM, et al., Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res 1998; 18: 4765-4768.
69. Rosen BJ, Walter L, Gilman RH, Cabrerra L, Gravitt PE, Marks MA,. Prevalence and correlates of oral human papillomavirus infection among healthy males and females in Lima, Peru [published online August 14, 2015 ]. Sex Transm Infect doi: 10.1136/sextrans-2014-051942.
70. Du J, Nordfors C, Ahrlund-Richter A, et al., Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg Infect Dis 2012; 18: 1468-1471.
71. Antonsson A, Cornford M, Perry S, Davis M, Dunne MP, Whiteman DC,. Prevalence and risk factors for oral HPV infection in young Australians. PLoS One 2014; 9: e91761.
72. Kurose K, Terai M, Soedarsono N, et al., Low prevalence of HPV infection and its natural history in normal oral mucosa among volunteers on Miyako Island, Japan. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 91-96.
73. Rintala M, Grenman S, Puranen M, Syrjanen S,. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 2006; 35: 89-94.